- Home
- AIRS vs XOMA Comparison
AIRS vs XOMA Comparison
Compare AIRS & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- XOMA
- Stock Information
- Founded
- AIRS 2012
- XOMA 1981
- Country
- AIRS United States
- XOMA United States
- Employees
- AIRS N/A
- XOMA N/A
- Industry
- AIRS Medical/Nursing Services
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- XOMA Health Care
- Exchange
- AIRS Nasdaq
- XOMA Nasdaq
- Market Cap
- AIRS 333.7M
- XOMA 319.3M
- IPO Year
- AIRS 2021
- XOMA N/A
- Fundamental
- Price
- AIRS $5.33
- XOMA $23.52
- Analyst Decision
- AIRS Hold
- XOMA Strong Buy
- Analyst Count
- AIRS 3
- XOMA 2
- Target Price
- AIRS $5.00
- XOMA $72.00
- AVG Volume (30 Days)
- AIRS 135.0K
- XOMA 58.5K
- Earning Date
- AIRS 03-04-2025
- XOMA 03-07-2025
- Dividend Yield
- AIRS N/A
- XOMA N/A
- EPS Growth
- AIRS N/A
- XOMA N/A
- EPS
- AIRS N/A
- XOMA N/A
- Revenue
- AIRS $188,780,000.00
- XOMA $21,606,000.00
- Revenue This Year
- AIRS N/A
- XOMA $511.37
- Revenue Next Year
- AIRS $9.18
- XOMA $26.92
- P/E Ratio
- AIRS N/A
- XOMA N/A
- Revenue Growth
- AIRS N/A
- XOMA 389.82
- 52 Week Low
- AIRS $2.92
- XOMA $21.27
- 52 Week High
- AIRS $9.20
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- AIRS 46.64
- XOMA 33.53
- Support Level
- AIRS $5.71
- XOMA $24.01
- Resistance Level
- AIRS $6.08
- XOMA $27.43
- Average True Range (ATR)
- AIRS 0.47
- XOMA 1.15
- MACD
- AIRS 0.04
- XOMA -0.22
- Stochastic Oscillator
- AIRS 46.13
- XOMA 0.00
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.